ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VIRX Viracta Therapeutics Inc

0.8102
-0.0298 (-3.55%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Viracta Therapeutics Inc NASDAQ:VIRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0298 -3.55% 0.8102 0.40 0.88 0.84 0.80 0.8212 33,087 05:00:07

Initial Statement of Beneficial Ownership (3)

04/03/2021 10:46pm

Edgar (US Regulatory)


FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Simon Barry J.
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/3/2021 

3. Issuer Name and Ticker or Trading Symbol

Viracta Therapeutics, Inc. [VIRX]
(Last)        (First)        (Middle)

C/O VIRACTA THERAPEUTICS, INC., 2533 S COAST HWY 101, SUITE 210
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

CARDIFF, CA 92007      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)  (1)12/15/2028 Common Stock 11190 $0.90 D  

Explanation of Responses:
(1) One forty-eighth (1/48th) of the Shares subject to the Option shall vest on the one (1) month anniversary of December 15, 2018 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan) through each such date.

Remarks:
Exhibit 24: Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Simon Barry J.
C/O VIRACTA THERAPEUTICS, INC.
2533 S COAST HWY 101, SUITE 210
CARDIFF, CA 92007
X



Signatures
/s/ Michael Mueller, as Attorney-in-Fact3/4/2021
**Signature of Reporting PersonDate

1 Year Viracta Therapeutics Chart

1 Year Viracta Therapeutics Chart

1 Month Viracta Therapeutics Chart

1 Month Viracta Therapeutics Chart

Your Recent History

Delayed Upgrade Clock